Selling, general and administrative costs for the quarter ended March 31, 2011 were $43.2 million, compared to $36.1 million in the comparable 2010 period. The increase was primarily due to the addition of the sales and reimbursement field force and infrastructure, and promotional and training activity in support of the launch of XIAFLEX for Dupuytren's in the U.S.
As of March 31, 2011, Auxilium had $130.9 million in cash, cash equivalents and short-term investments, compared to $128.2 million at December 31, 2010.
Conference CallAuxilium will hold a conference call today, May 9, 2011 at 10:00 a.m. ET, to discuss first quarter 2011 results and operational highlights. The presentation slides to be used during the call are now available on the "For Investors" section of the Company's web site under the "Presentations" tab. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously web cast on the "For Investors" section of the Company's web site under the "Events" tab. The conference call will be archived for future review until June 9, 2011.
Conference call details: Date:Monday, May 9, 2011Time:10:00 a.m. ETDial-in (U.S.):866-314-4483Dial-in (International):617-213-8049Web cast:http://www.auxilium.com Passcode:AUXILIUMTo access an audio replay of the call:Access number (U.S.):888-286-8010Access number (International):617-801-6888Replay Passcode #:77302853About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists. Auxilium marke
|SOURCE Auxilium Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved